Obesity Treatment Market – Global Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Obesity Treatment Market

Market Size in USD Billion

CAGR : 14.70 %

Bar chart comparing the Global Obesity Treatment Market size in 2024 - 38.46 and 2032 - 115.26, highlighting the projected market growth.

USD 38.46 Million USD 115.26 Million 2024 2032

Forecast Period	2025 –2032
Market Size (Base Year)	USD 38.46 Million
Market Size (Forecast Year)	USD 115.26 Million
CAGR	14.70 %
Major Markets Players	Dummy1 Dummy2 Dummy3 Dummy4 Dummy5 Request For Unlock

Global Obesity Treatment Market Segmentation, By Treatment Type (Pharmacological Treatments (Anti-obesity Drugs), Bariatric Surgery, Behavioral & Lifestyle Therapy, Non-Invasive/ Endoscopic Procedures, and Medical Devices & Technologies), Age Group (Adult Obesity Treatment, Geriatric Obesity Treatment, and Pediatric Obesity Treatment), Distribution Channel (Online Pharmacies, Retail Pharmacies, Weight Management Clinics, Hospital Pharmacies, and Wellness & Fitness Centers), Patient Type (Class III, Class II, and Class I) - Industry Trends and Forecast to 2032

Global Obesity Treatment Market Size

The global obesity treatment market was valued at USD 38.46 million in 2024 and is expected to reach USD 115.26 million by 2032
During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 14.7% primarily driven by the increasing prevalence of obesity.
This growth is driven by factors such as innovations in anti-obesity medications, growth in bariatric and metabolic surgeries. In addition, integration of digital health solutions in obesity treatment.

Global Obesity Treatment Market Analysis

Obesity is a chronic medical condition characterized by excessive fat accumulation, increasing the risk of severe health complications such as cardiovascular diseases, type 2 diabetes, hypertension, and certain cancers
Treatment options range from lifestyle modifications, pharmacotherapy, and medical devices to bariatric surgery, aiming to achieve sustainable weight loss and improve overall health outcomes
The global obesity treatment market is driven by the rising prevalence of obesity due to sedentary lifestyles, unhealthy dietary habits, and genetic predisposition. Pharmacological interventions, including GLP-1 receptor agonists and appetite suppressants, play a crucial role in weight management, alongside behavioral therapy and lifestyle changes. Bariatric surgeries, such as gastric bypass and sleeve gastrectomy, are also gaining traction as effective long-term solutions for severe obesity
The increasing demand for minimally invasive procedures and innovative anti-obesity medications is further propelling market growth
North America remains a dominant region in the global obesity treatment market, supported by well-established healthcare infrastructure, high obesity rates, and continuous research in weight management solutions

For instance, the U.S. leads in the adoption of GLP-1 receptor agonists like semaglutide and liraglutide, along with advancements in non-invasive medical devices designed for weight loss

With a growing emphasis on obesity management and preventive healthcare, the global market is witnessing significant investments in novel therapies, medical technologies, and patient-centric solutions, driving overall industry expansion

Report Scope and Obesity Treatment Market Segmentation

Attributes	Global Obesity Treatment Market Key Market Insights
Segments Covered	By Treatment Type- Pharmacological Treatments (Anti-obesity Drugs), Bariatric Surgery, Behavioral & Lifestyle Therapy, Non-Invasive/ Endoscopic Procedures, and Medical Devices & Technologies By Age Group -Adult Obesity Treatment, Geriatric Obesity Treatment, and Pediatric Obesity Treatment By Distribution Channel- Online Pharmacies, Retail Pharmacies, Weight Management Clinics, Hospital Pharmacies, and Wellness & Fitness Centers. By Patient Type -Class III, Class II, and Class I
Countries Covered	North America. U.S. Canada Mexico Europe Germany U.K. France Russia Italy Spain Turkey Poland Netherlands Switzerland Norway Austria Ireland Rest of Europe Asia- Pacific China Japan India Australia South Korea Singapore Thailand Philippines Malaysia Indonesia Vietnam Taiwan Rest of Asia-Pacific South America Brazil Argentina Chile Peru Rest of South America Middle East and Africa Saudi Arabia U.A.E. South Africa Egypt Kuwait Israel Rest of Middle East and Africa
Key Market Players	Novo Nordisk A/S (Denmark) Eli Lilly and Company (U.S.) Medtronic (U.S.) Boston Scientific Corporation (U.S.) Johnson & Johnson Services, Inc. (U.S.) Altimmune (U.S.) AstraZeneca (UK) Allurion (U.S.) Amgen Inc. (U.S.) Arena Pharmaceuticals Ltd (U.S.) Currax pharmaceuticals LLC (U.S.) COUSIN SURGERY (France) F. Hoffmann-La Roche Ltd (Switzerland) Fitterfly Healthtech Pvt. Ltd. (India) Morphic Medical, Inc (U.S.) Noom, Inc. (U.S.) Omada Health Inc (U.S.) Reshape Lifesciences Inc. (U.S.) Raziel (Isarel) Spatz FGIA Inc. (U.S.) Sanofi (France) Saniona (Denmark) USGI Medical (U.S.) VIVUS LLC. (U.S.) Viking Therapeutics (U.S.)
Market Opportunities	Increasing prevalence of lifestyle related diseases Rising disposable income enhancing the purchasing power for obesity treatment related products
Value Added Data Infosets	In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

Global Obesity Treatment Market Trends.

“Rising Adoption of Digital and AI-Driven Weight Management Solutions”

A key trend in the global obesity treatment market is the increasing adoption of digital and AI-driven weight management solutions
These innovative technologies enhance obesity management by providing personalized treatment plans, real-time monitoring, and data-driven insights to optimize weight loss strategies
For instance, AI-powered mobile applications and wearable devices track physical activity, caloric intake, and metabolic rates, offering tailored recommendations to improve adherence and outcomes
Telemedicine platforms and virtual coaching further support patients by providing remote consultations, behavioral counseling, and medication management, leading to more effective and sustainable weight loss
This trend is revolutionizing obesity care by improving patient engagement, enhancing long-term treatment success, and driving demand for digital health solutions in the obesity treatment market

Global Obesity Treatment Market Dynamics

Driver

“Increasing Prevalence of Obesity”

The obesity epidemic is escalating due to sedentary lifestyles, poor dietary habits, and genetic predisposition, leading to a sharp increase in obesity-related health complications such as diabetes, cardiovascular diseases, and hypertension
Urbanization and technological advancements have contributed to reduced physical activity, while widespread consumption of processed and high-calorie foods has further fueled weight gain
Genetic factors also play a significant role, with many individuals being predisposed to metabolic disorders that contribute to obesity. As obesity rates continue to surge, the demand for effective treatment solutions, including pharmacological therapies, bariatric surgeries, and medically supervised weight management programs, is rising significantly

For instance,

In March 2024, as per the information provided by WHO, the Europe obesity epidemic is escalating, with 1 in 8 people living with obesity in 2022. Adult obesity has doubled since 1990, and adolescent obesity has quadrupled. Over 2.5 billion adults were overweight, including 890 million with obesity. Rising obesity rates contribute to increased risks of diabetes, heart disease, and cancer, fueling demand for effective treatments and driving market growth
In September 2024, as highlighted by the Centers for Disease Control and Prevention, between August 2021 and August 2023, 40.3% of adults were living with obesity, with 39.2% of men and 41.3% of women affected. The highest prevalence was among adults aged 40–59 (46.4%), followed by 20–39 (35.5%) and 60+ (38.9%). The increasing obesity burden is expected to drive demand for effective obesity treatments
In 2024, as mentioned by World Obesity Atlas, by 2035, 79% of overweight and obese adults and 88% of overweight and obese children will reside in Low- and Middle-Income Countries (LMICs). The number of adults with obesity is projected to increase from 0.81 billion in 2020 to 1.53 billion in 2035. This rising prevalence is increasing the demand for obesity treatment solutions, driving market growth
This growing patient burden is driving healthcare providers, pharmaceutical companies, and wellness programs to expand their offerings, making the rising prevalence of obesity a key driver for the Europe obesity treatment market

Opportunity

“Increasing Prevalence of Lifestyle Related Diseases”

As more individuals seek to manage their weight and mitigate associated health risks, pharmaceutical companies and healthcare providers are incentivized to innovate and expand their offerings
This trend fosters the development of new medications, surgical options, and comprehensive lifestyle programs tailored to diverse patient needs

For instance,

In May 2023, NCBI stated that it is estimated that more than 1 billion people will be living with obesity by 2030.1 The higher rates of obesity-associated mortality and comorbidities, such as diabetes, cardiovascular disease, chronic kidney disease, and several types of cancer, are equally staggering, with an average of 5 million deaths and 160 million disability-adjusted life-years
In June 2023, according to an article published by Acta Pharmaceutica Sinica B, obesity strongly contributes to the development of cancer, cardiovascular diseases, type 2 diabetes, liver diseases and other disorders
In April 2021, according to an article published in the American Heart Association Journals, Obesity contributes directly to incident cardiovascular risk factors, including dyslipidemia, type 2 diabetes, hypertension, and sleep disorders. Obesity also leads to the development of cardiovascular disease and cardiovascular disease mortality independently of other cardiovascular risk factors
In April 2023, a study by MoneyControl outlined that India has experienced a massive spike in lifestyle diseases, including an increase in the prevalence of early risk factors like obesity and cholesterol irregularities

In addition, heightened awareness regarding the health consequences of obesity encourages proactive health management among consumers. With supportive initiatives from governments and health organizations promoting healthier lifestyles, the obesity treatment market is poised for substantial growth
This momentum attracts investment and boosts research and development efforts, paving the way for a wide range of therapeutic interventions to meet the needs of an expanding patient population

Restraint/Challenge

“Long-Term Follow-Ups Associated With Obesity Treatment”

Long-term follow-ups associated with obesity treatment primarily due to the complexity and resource intensiveness of such programs often requires continuous monitoring and support to ensure sustained weight loss and management, which can include regular consultations, nutritional guidance, and behavioral therapy
These long-term commitments burden healthcare systems and pose logistical challenges for both patients and providers, leading to potential gaps in care and inconsistent treatment adherence

For instance,

In December 2022, as per AJMC, managing obesity requires the ongoing partnership of a committed patient and informed clinicians. Managing obesity requires the ongoing partnership of a committed patient and informed clinicians
In September 2022, JAMA Network reported that, in research carried for 175 patients, 94 (53.7%) had weight loss of at least 5% and 26 (14.9%) had weight loss of 10% or more at 3 months. Of 102 patients who were followed up for 6 months, 89 (87.3%) achieved weight loss of 5% or more, 56 (54.9%) achieved weight loss of 10% or more, 24 (23.5%) achieved weight loss of 15% or more, and 8 (7.8%) achieved weight loss of 20% or more
In November 2021, according to an article published by the National Library of Medicine, ensuring a long-term follow-up seems to be of the utmost importance for bariatric patients. Low quality follow-up in bariatric surgery is indicated as a risk factor for poor outcomes but the versatility and effectiveness of follow-up are also determinants of clinical research

Moreover, the necessity for long-term follow-ups deters individuals from seeking treatment initially. Many prospective patients may be apprehensive about the ongoing commitment and costs associated with regular check-ins and monitoring, which is perceived as daunting or inconvenient
This hesitancy impedes market growth, as potential consumers shy away from programs that require sustained engagement and accountability
Consequently, the challenge of facilitating effective long-term follow-ups may limit the overall effectiveness of obesity treatments and their acceptance among the target population

Global Obesity Treatment Market Scope

The market is segmented on the basis of type, product type, absorption site, age group, source, delivery method, gender, and distribution channel.

Segmentation	Sub-Segmentation
Treatment Type	Pharmacological Treatments (Anti-obesity Drugs) GLP-1 Receptor Agonists Dual GIP/ GLP-1 Receptor Agonists Centrally Acting Anorectics Phentermine Phentermine-Topiramate Naltrexone-Bupropion Lipase Inhibitors Deoxycholic Acid Others Bariatric Surgery By Type Restrictive Surgeries Sleeve gastrectomy Adjustable gastric banding Combination Surgeries Roux-en-Y gastric bypass (RYGB) Mini-gastric bypass (MGB) Malabsorptive Surgeries By Approach Laparoscopic Surgery Robotic-Assisted Surgery Open Surgery Behavioral & Lifestyle Therapy Dietary Interventions Behavioral Modification Therapy Physical Activity Programs Psychological Counseling Non-Invasive/ Endoscopic Procedures Endoscopic Sleeve Gastroplasty (ESG) Intragastric Balloon (IGB) Orbera intragastric balloon Spatz adjustable balloon system Aspiration Therapy (AspireAssist) Transoral Gastroplasty (TOGA) Medical Devices & Technologies Artificial Intelligence & Digital Weight Management Platforms Gastric Electrical Stimulation Devices (Maestro System)
Age Group	Adult Obesity Treatment Geriatric Obesity Treatment Pediatric Obesity Treatment
Distribution Channel-	Online Pharmacies Retail Pharmacies Weight Management Clinics Hospital Pharmacies Wellness & Fitness Centers
Patient Type	Class III Class II Class I

Global obesity treatment market Regional Analysis

“North America is the Dominant Region in the Insulin Market for Type 1 and Type 2 Diabetes”

North America leads the global obesity treatment market, driven by a high prevalence of obesity, advanced healthcare infrastructure, and strong adoption of innovative weight management solutions
The U.S. holds a significant market share due to the rising demand for pharmacological treatments like GLP-1 receptor agonists, bariatric surgeries, and digital weight management platforms
In addition, increasing awareness about obesity-related health risks and the growing adoption of AI-driven weight loss programs, telehealth consultations, and non-invasive treatment solutions continue to fuel market expansion in the region

“South America is Projected to Register the Highest Growth Rate”

The South American region is expected to witness the highest growth rate in the global obesity treatment market, driven by increasing obesity prevalence, rising healthcare investments, and growing awareness about weight management solutions.
Countries such as Brazil, Argentina, and Chile are emerging as key markets due to shifting lifestyle patterns, rising urbanization, and an increasing number of obesity-related health complications.
Brazil, with its expanding healthcare infrastructure and growing demand for medical weight loss treatments, remains a crucial market for obesity management. The country is witnessing increased adoption of pharmacological treatments, bariatric surgeries, and digital weight management programs.

Global Obesity Treatment Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

Novo Nordisk A/S (Denmark)
Eli Lilly and Company (U.S.)
Medtronic (U.S.)
Boston Scientific Corporation (U.S.)
Johnson & Johnson Services, Inc. (U.S.)
Altimmune (U.S.)
AstraZeneca (UK)
Allurion (U.S.)
Amgen Inc. (U.S.)
Arena Pharmaceuticals Ltd (U.S.)
Currax pharmaceuticals LLC (U.S.)
COUSIN SURGERY (France)
F. Hoffmann-La Roche Ltd (Switzerland)
Fitterfly Healthtech Pvt. Ltd. (India)
Morphic Medical, Inc (U.S.)
Noom, Inc. (U.S.)
Omada Health Inc (U.S.)
Reshape Lifesciences Inc. (U.S.)
Raziel (Isarel)
Spatz FGIA Inc. (U.S.)
Sanofi (France)
Saniona (Denmark)
USGI Medical (U.S.)
VIVUS LLC. (U.S.)
Viking Therapeutics (U.S.)

Latest Developments in Global Obesity Treatment Market

In October 2024, VIVUS and UpScriptHealth have launched ChooseQ. online, a telehealth platform that offers convenient access to QSYMIA for weight management. This service allows patients to consult with healthcare providers online and receive QSYMIA directly at home. This initiative aims to improve accessibility to obesity treatment through telemedicine
In October 2024, Zealand Pharma announced that Boehringer Ingelheim received U.S. FDA Breakthrough Therapy designation for Survodutide (BI 456906) for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate or advanced fibrosis. This designation accelerates its development due to promising Phase II results
In March 2025, Zealand Pharma announced the completion of participant enrolment in the Phase 2b ZUPREME-1 trial for Petrelintide, a long-acting amylin analog aimed at treating overweight and obesity. The trial will assess the effects of various doses of Petrelintide on body weight, safety, and tolerability over 42 weeks, with results expected in 2025
On March 2025, Raziel Therapeutics, a pharmaceutical company focused on next-generation prescription products for the medical aesthetics market, has announced the initiation of a Phase 3 clinical study in China for RZL-012, aimed at reducing submental fat (SMF). SMF reduction is the first indication for RZL-012, with potential applications for various aesthetic fat reduction treatments in body shaping
In October 2022, ReShape Lifesciences, a leader in weight loss and metabolic health solutions, announced that the American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) have released updated guidelines for Metabolic and Bariatric Surgery, which now include the Lap-Band. These guidelines replace the previous 30-year-old standards established by the National Institutes of Health (NIH) in 1991

SKU-73838

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE GLOBAL OBESITY TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 MULTIVARIATE MODELLING

2.6 TREATMENT TYPE LIFELINE CURVE

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 MARKET END USER COVERAGE GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 EPIDEMIOLOGY: GLOBAL OBESITY TREATMENT MARKET

4.4 DRUG TREATMENT RATE BY MATURED MARKETS: GLOBAL OBESITY TREATMENT MARKET

4.5 DRUG

4.6 WORD PIPELINE

5 REGULATORY FRAMEWORK FOR THE GLOBAL OBESITY TREATMENT MARKET

5.1 REGULATORY APPROVAL PATHWAYS

5.2 LICENSING AND REGISTRATION

5.3 REGULATORY APPROVAL PATHWAYS

5.4 LICENSING AND REGISTRATION

5.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF OBESITY

6.1.2 INNOVATIONS IN ANTI-OBESITY MEDICATIONS

6.1.3 GROWTH IN BARIATRIC AND METABOLIC SURGERIES.

6.1.4 INTEGRATION OF DIGITAL HEALTH SOLUTIONS IN OBESITY TREATMENT

6.2 RESTRAINTS

6.2.1 ANTI-OBESITY DRUGS AND SURGICAL INTERVENTIONS CARRY RISKS

6.2.2 HIGH RELAPSE RATES POST-TREATMENT OF OBESITY

6.3 OPPORTUNITIES

6.3.1 INCREASING PREVALENCE OF LIFESTYLE RELATED DISEASES

6.3.2 RISING DISPOSABLE INCOME ENHANCING THE PURCHASING POWER FOR OBESITY TREATMENT RELATED PRODUCTS

6.3.3 RISE IN STRATEGIC INITIATIVES AND LAUNCHES BY MARKET PLAYERS

6.4 CHALLENGES

6.4.1 LONG-TERM FOLLOW-UPS ASSOCIATED WITH OBESITY TREATMENT

6.4.2 ADDRESSAL OF THE LIFESTYLE AND BEHAVIORAL CHANGES

7 GLOBAL OBESITY TREATMENT MARKET, BY TREATMENT TYPE

7.1 OVERVIEW

7.2 PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS)

7.2.1 GLP-1 RECEPTOR AGONISTS

7.2.2 DUAL GIP/ GLP-1 RECEPTOR AGONISTS

7.2.2.1 PHENTERMINE

7.2.2.2 PHENTERMINE-TOPIRAMATE

7.2.2.3 NALTREXONE-BUPROPION

7.2.3 LIPASE INHIBITORS

7.2.4 DEOXYCHOLIC ACID

7.2.5 OTHERS

7.3 BARIATRIC SURGERY

7.3.1 RESTRICTIVE SURGERIES

7.3.1.1 SLEEVE GASTRECTOMY

7.3.1.2 ADJUSTABLE GASTRIC BANDING

7.3.2 COMBINATION SURGERIES

7.3.2.1 ROUX-EN-Y GASTRIC BYPASS (RYGB)

7.3.2.2 MINI-GASTRIC BYPASS (MGB)

7.3.3 MALABSORPTIVE SURGERIES

7.3.3.1 LAPAROSCOPIC SURGERY

7.3.3.2 ROBOTIC-ASSISTED SURGERY

7.3.3.3 OPEN SURGERY

7.4 BEHAVIORAL & LIFESTYLE THERAPY

7.4.1 DIETARY INTERVENTIONS

7.4.2 BEHAVIORAL MODIFICATION THERAPY

7.4.3 PHYSICAL ACTIVITY PROGRAMS

7.4.4 PSYCHOLOGICAL COUNSELING

7.5 NON-INVASIVE/ ENDOSCOPIC PROCEDURES

7.5.1 ENDOSCOPIC SLEEVE GASTROPLASTY (ESG)

7.5.2 INTRAGASTRIC BALLOON (IGB)

7.5.2.1 ORBERA INTRAGASTRIC BALLOON

7.5.2.2 SPATZ ADJUSTABLE BALLOON SYSTEM

7.5.3 ASPIRATION THERAPY (ASPIREASSIST)

7.5.4 TRANSORAL GASTROPLASTY (TOGA)

7.6 MEDICAL DEVICES & TECHNOLOGIES

7.6.1 ARTIFICIAL INTELLIGENCE & DIGITAL WEIGHT MANAGEMENT PLATFORMS

7.6.2 GASTRIC ELECTRICAL STIMULATION DEVICES (MAESTRO SYSTEM)

8 GLOBAL OBESITY TREATMENT MARKET, BY AGE GROUP

8.1 OVERVIEW

8.2 ADULT OBESITY TREATMENT

8.3 GERIATRIC OBESITY TREATMENT

8.4 PEDIATRIC OBESITY TREATMENT

9 GLOBAL OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW

9.2 ONLINE PHARMACIES

9.3 RETAIL PHARMACIES

9.4 WEIGHT MANAGEMENT CLINICS

9.5 HOSPITAL PHARMACIES

9.6 WELLNESS & FITNESS CENTERS

10 GLOBAL OBESITY TREATMENT MARKET, BY PATIENT TYPE

10.1 OVERVIEW

10.2 CLASS III

10.3 CLASS II

10.4 CLASS I

11 GLOBAL OBESITY TREATMENT MARKET, BY REGION

11.1 OVERVIEW

11.2 NORTH AMERICA

11.2.1 U.S.

11.2.2 MEXICO

11.2.3 CANADA

11.3 EUROPE

11.3.1 UNITED KINGDOM

11.3.2 GERMANY

11.3.3 FRANCE

11.3.4 ITALY

11.3.5 SPAIN

11.3.6 RUSSIA

11.3.7 TURKEY

11.3.8 NETHERLANDS

11.3.9 SWITZERLAND

11.3.10 POLAND

11.3.11 IRELAND

11.3.12 AUSTRIA

11.3.13 NORWAY

11.3.14 REST OF EUROPE

11.4 ASIA-PACIFIC

11.4.1 CHINA

11.4.2 JAPAN

11.4.3 INDIA

11.4.4 AUSTRALIA

11.4.5 SOUTH KOREA

11.4.6 TAIWAN

11.4.7 SINGAPORE

11.4.8 MALAYSIA

11.4.9 THAILAND

11.4.10 INDONESIA

11.4.11 PHILIPPINES

11.4.12 VIETNAM

11.4.13 REST OF ASIA-PACIFIC

11.5 MIDDLE EAST AND AFRICA

11.5.1 SAUDI ARABIA

11.5.2 EGYPT

11.5.3 KUWAIT

11.5.4 SOUTH AFRICA

11.5.5 UNITED ARAB EMIRATES

11.5.6 ISRAEL

11.5.7 REST OF MIDDLE EAST AND AFRICA

11.6 SOUTH AMERICA

11.6.1 BRAZIL

11.6.2 ARGENTINA

11.6.3 CHILE

11.6.4 PERU

11.6.5 REST OF SOUTH AMERICA

12 GLOBAL OBESITY TREATMENT MARKET, COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: GLOBAL

12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

12.3 COMPANY SHARE ANALYSIS: EUROPE

12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 NOVO NORDISK A/S

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENT

14.2 ELI LILLY AND COMPANY

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENT/NEWS

14.3 MEDTRONIC

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENT

14.4 BOSTON SCIENTIFIC CORPORATION

14.4.1 COMPANY SNAPSHOTS

14.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENT

14.5 JOHNSON & JOHNSON SERVICES, INC.

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENT/NEWS

14.6 ALTIMMUNE

14.6.1 COMPANY SNAPSHOT

14.6.2 PIPELINE PORTFOLIO

14.6.3 RECENT UPDATES

14.7 ASTRAZENECA

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENT/NEWS

14.8 ALLURION

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

1.1.5 RECENT DEVELOPMENT/NEWS 421

14.9 AMGEN

14.9.1 COMPANY SNAPSHOT

14.9.2 REVENUE ANALYSIS

14.9.3 PRODUCT PORTFOLIO

1.1.13 RECENT DEVELOPMENT/NEWS 426

14.1 ARENA PHARMACEUTICALS LTD

14.10.1 COMPANY SNAPSHOT

14.10.2 PRODUCT PORTFOLIO

14.10.3 RECENT DEVELOPMENT

14.11 CURRAX PHARMACEUTICALS LLC

14.11.1 COMPANY SNAPSHOT

14.11.2 PRODUCT PORTFOLIO

14.11.3 RECENT DEVELOPMENT

14.12 COUSIN SURGERY

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENT

14.13 F. HOFFMANN-LA ROCHE LTD

14.13.1 COMPANY SNAPSHOT

14.13.2 REVENUE ANALYSIS

14.13.3 PRODUCT PORTFOLIO

14.13.4 RECENT DEVELOPMENT/NEWS

14.14 FITTERFLY HEALTHTECH PVT. LTD.

14.14.1 COMPANY SNAPSHOT

14.14.2 PRODUCT PORTFOLIO

14.14.3 RECENT DEVELOPMENT

14.15 MORPHIC MEDICAL, INC

14.15.1 COMPANY SNAPSHOT

14.15.2 PRODUCT PORTFOLIO

14.15.3 RECENT DEVELOPMENT

14.16 NOOM, INC.

14.16.1 COMPANY SNAPSHOT

14.16.2 PRODUCT PORTFOLIO

14.16.3 RECENT DEVELOPMENT

14.17 OMADA HEALTH INC

14.17.1 COMPANY SNAPSHOT

14.17.2 PRODUCT PORTFOLIO

14.17.3 RECENT DEVELOPMENT

14.18 RESHAPE LIFESCIENCES

14.18.1 COMPANY SNAPSHOT

14.18.2 REVENUE ANALYSIS

14.18.3 PRODUCT PORTFOLIO

1.1.7 RECENT DEVELOPMENT/NEWS 445

14.19 RAZIEL

14.19.1 COMPANY SNAPSHOT

14.19.2 PRODUCT PORTFOLIO

14.19.3 RECENT DEVELOPMENT

14.2 SPATZ FGIA INC.

14.20.1 COMPANY SNAPSHOT

14.20.2 PRODUCT PORTFOLIO

14.20.3 RECENT DEVELOPMENT

14.21 SANOFI

14.21.1 COMPANY SNAPSHOT

14.21.2 REVENUE ANALYSIS

14.21.3 PRODUCT PORTFOLIO

14.21.4 RECENT DEVELOPMENT

14.22 SANIONA

14.22.1 COMPANY SNAPSHOT

14.22.2 REVENUE ANALYSIS

14.22.3 PRODUCT PORTFOLIO

14.22.4 RECENT DEVELOPMENT

14.23 USGI MEDICAL

14.23.1 COMPANY SNAPSHOT

14.23.2 PRODUCT PORTFOLIO

14.23.3 RECENT DEVELOPMENT

14.24 VIVUS LLC.

14.24.1 COMPANY SNAPSHOT

14.24.2 PRODUCT PORTFOLIO

14.24.3 RECENT DEVELOPMENT/NEWS

14.25 VIKING THERAPEUTICS

14.25.1 COMPANY SNAPSHOTS

14.25.2 REVENUE ANALYSIS

14.25.3 PRODUCT PORTFOLIO

14.25.4 RECENT DEVELOPMENT

14.26 ZEALAND PHARMA

14.26.1 COMPANY SNAPSHOT

14.26.2 REVENUE ANALYSIS

14.26.3 PRODUCT PORTFOLIO

14.26.4 RECENT DEVELOPMENT/NEWS

15 QUESTIONNAIRE

16 RELATED REPORTS

List of Table

TABLE 1 OBESITY PREVALENCE BY REGION (ADULTS)

TABLE 2 OBESITY PREVALENCE BY GENDER (ADULTS)

TABLE 3 OBESITY PREVALENCE BY AGE (ADULTS)

TABLE 4 GLOBAL CLINICAL TRIAL MARKET FOR OBESITY TREATMENT

TABLE 5 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE GLOBAL OBESITY TREATMENT MARKET

TABLE 6 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE GLOBAL OBESITY TREATMENT MARKET

TABLE 7 GLOBAL OBESITY STATISTICS (2022)

TABLE 8 GLOBAL OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 9 GLOBAL PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 10 GLOBAL PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 11 GLOBAL CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 12 GLOBAL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 13 GLOBAL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 14 GLOBAL RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 15 GLOBAL COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 16 GLOBAL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 17 GLOBAL BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 18 GLOBAL BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 19 GLOBAL NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 20 GLOBAL NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 21 GLOBAL INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 22 GLOBAL MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 23 GLOBAL MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 24 GLOBAL OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 25 GLOBAL ADULT OBESITY TREATMENT IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 26 GLOBAL GERIATRIC OBESITY TREATMENT IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 27 GLOBAL PEDIATRIC OBESITY TREATMENT IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 28 GLOBAL OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 29 GLOBAL ONLINE PHARMACIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 30 GLOBAL RETAIL PHARMACIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 31 GLOBAL WEIGHT MANAGEMENT CLINICS IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 32 GLOBAL HOSPITAL PHARMACIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 33 GLOBAL WELLNESS & FITNESS CENTERS IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 34 GLOBAL OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 35 GLOBAL CLASS III IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 36 GLOBAL CLASS II IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 37 GLOBAL CLASS I IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 38 GLOBAL OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 39 NORTH AMERICA OBESITY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 40 NORTH AMERICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 41 NORTH AMERICA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 42 NORTH AMERICA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 43 NORTH AMERICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 44 NORTH AMERICA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 45 NORTH AMERICA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 46 NORTH AMERICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 47 NORTH AMERICA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 48 NORTH AMERICA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 49 NORTH AMERICA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 50 NORTH AMERICA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 51 NORTH AMERICA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 52 NORTH AMERICA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 53 NORTH AMERICA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 54 U.S. OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 55 U.S. PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 56 U.S. CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 57 U.S. BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 58 U.S. RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 59 U.S. COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 60 U.S. BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 61 U.S. BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 62 U.S. NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 63 U.S. INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 64 U.S. MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 65 U.S OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 66 U.S. OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 67 U.S. OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 68 MEXICO OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 69 MEXICO PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 70 MEXICO CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 71 MEXICO BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 72 MEXICO RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 73 MEXICO COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 74 MEXICO BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 75 MEXICO BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 76 MEXICO NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 77 MEXICO INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 78 MEXICO MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 79 MEXICO OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 80 MEXICO OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 81 MEXICO OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 82 CANADA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 83 CANADA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 84 CANADA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 85 CANADA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 86 CANADA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 87 CANADA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 88 CANADA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 89 CANADA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 90 CANADA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 91 CANADA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 92 CANADA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 93 CANADA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 94 CANADA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 95 CANADA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 96 EUROPE OBESITY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 97 EUROPE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 98 EUROPE PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 99 EUROPE CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 100 EUROPE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 101 EUROPE RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 102 EUROPE COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 103 EUROPE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 104 EUROPE BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 105 EUROPE NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 106 EUROPE INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 107 EUROPE MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 108 EUROPE OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 109 EUROPE OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 110 EUROPE OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 111 UNITED KINGDOM OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 112 UNITED KINGDOM PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 113 UNITED KINGDOM CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 114 UNITED KINGDOM BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 115 UNITED KINGDOM RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 116 UNITED KINGDOM COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 117 UNITED KINGDOM BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 118 UNITED KINGDOM BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 119 UNITED KINGDOM NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 120 UNITED KINGDOM INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 121 UNITED KINGDOM MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 122 UNITED KINGDOM OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 123 UNITED KINGDOM OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 124 UNITED KINGDOM OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 125 GERMANY OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 126 GERMANY PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 127 GERMANY CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 128 GERMANY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 129 GERMANY RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 130 GERMANY COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 131 GERMANY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 132 GERMANY BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 133 GERMANY NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 134 GERMANY INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 135 GERMANY MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 136 GERMANY OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 137 GERMANY OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 138 GERMANY OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 139 FRANCE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 FRANCE PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 141 FRANCE CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 142 FRANCE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 143 FRANCE RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 144 FRANCE COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 145 FRANCE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 146 FRANCE BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 147 FRANCE NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 148 FRANCE INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 149 FRANCE MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 150 FRANCE OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 151 FRANCE OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 152 FRANCE OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 153 ITALY OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 ITALY PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 ITALY CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 156 ITALY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 157 ITALY RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 158 ITALY COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 159 ITALY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 160 ITALY BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 161 ITALY NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 162 ITALY INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 163 ITALY MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 164 ITALY OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 165 ITALY OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 166 ITALY OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 167 SPAIN OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 168 SPAIN PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 169 SPAIN CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 170 SPAIN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 171 SPAIN RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 172 SPAIN COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 173 SPAIN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 174 SPAIN BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 175 SPAIN NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 176 SPAIN INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 177 SPAIN MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 178 SPAIN OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 179 SPAIN OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 180 SPAIN OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 181 RUSSIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 182 RUSSIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 183 RUSSIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 184 RUSSIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 185 RUSSIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 186 RUSSIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 187 RUSSIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 188 RUSSIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 189 RUSSIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 190 RUSSIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 191 RUSSIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 192 RUSSIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 193 RUSSIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 194 RUSSIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 195 TURKEY OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 196 TURKEY PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 197 TURKEY CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 198 TURKEY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 199 TURKEY RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 200 TURKEY COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 201 TURKEY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 202 TURKEY BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 203 TURKEY NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 204 TURKEY INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 205 TURKEY MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 206 TURKEY OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 207 TURKEY OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 208 TURKEY OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 209 NETHERLANDS OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 210 NETHERLANDS PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 211 NETHERLANDS CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 212 NETHERLANDS BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 213 NETHERLANDS RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 214 NETHERLANDS COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 215 NETHERLANDS BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 216 NETHERLANDS BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 NETHERLANDS NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 218 NETHERLANDS INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 219 NETHERLANDS MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 220 NETHERLANDS OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 221 NETHERLANDS OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 222 NETHERLANDS OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 223 SWITZERLAND OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 224 SWITZERLAND PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 225 SWITZERLAND CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 226 SWITZERLAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 227 SWITZERLAND RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 228 SWITZERLAND COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 229 SWITZERLAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 230 SWITZERLAND BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 231 SWITZERLAND NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 232 SWITZERLAND INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 233 SWITZERLAND MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 234 SWITZERLAND OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 235 SWITZERLAND OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 236 SWITZERLAND OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 237 POLAND OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 238 POLAND PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 239 POLAND CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 240 POLAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 241 POLAND RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 242 POLAND COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 243 POLAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 244 POLAND BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 245 POLAND NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 POLAND INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 247 POLAND MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 248 POLAND OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 249 POLAND OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 250 POLAND OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 251 IRELAND OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 252 IRELAND PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 253 IRELAND CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 254 IRELAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 255 IRELAND RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 256 IRELAND COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 257 IRELAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 258 IRELAND BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 259 IRELAND NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 260 IRELAND INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 261 IRELAND MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 262 IRELAND OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 263 IRELAND OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 264 IRELAND OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 265 AUSTRIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 266 AUSTRIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 267 AUSTRIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 268 AUSTRIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 269 AUSTRIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 270 AUSTRIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 271 AUSTRIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 272 AUSTRIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 AUSTRIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 274 AUSTRIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 275 AUSTRIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 276 AUSTRIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 277 AUSTRIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 278 AUSTRIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 279 NORWAY OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 280 NORWAY PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 281 NORWAY CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 282 NORWAY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 283 NORWAY RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 284 NORWAY COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 285 NORWAY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 286 NORWAY BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 287 NORWAY NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 288 NORWAY INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 289 NORWAY MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 290 NORWAY OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 291 NORWAY OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 292 NORWAY OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 293 REST OF EUROPE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 294 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 295 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 296 ASIA-PACIFIC PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 297 ASIA-PACIFIC CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 298 ASIA-PACIFIC BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 299 ASIA-PACIFIC RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 300 ASIA-PACIFIC COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 301 ASIA-PACIFIC BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 302 ASIA-PACIFIC BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 303 ASIA-PACIFIC NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 304 ASIA-PACIFIC INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 305 ASIA-PACIFIC MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 306 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 307 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 308 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 309 CHINA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 310 CHINA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 311 CHINA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 312 CHINA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 313 CHINA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 314 CHINA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 315 CHINA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 316 CHINA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 317 CHINA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 318 CHINA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 319 CHINA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 320 CHINA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 321 CHINA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 322 CHINA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 323 JAPAN OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 324 JAPAN PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 325 JAPAN CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 326 JAPAN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 327 JAPAN RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 328 JAPAN COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 329 JAPAN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 330 JAPAN BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 331 JAPAN NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 332 JAPAN INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 333 JAPAN MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 334 JAPAN OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 335 JAPAN OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 336 JAPAN OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 337 INDIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 338 INDIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 339 INDIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 340 INDIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 341 INDIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 342 INDIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 343 INDIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 344 INDIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 345 INDIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 346 INDIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 347 INDIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 348 INDIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 349 INDIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 350 INDIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 351 AUSTRALIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 352 AUSTRALIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 353 AUSTRALIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 354 AUSTRALIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 355 AUSTRALIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 356 AUSTRALIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 357 AUSTRALIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 358 AUSTRALIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 359 AUSTRALIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 360 AUSTRALIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 361 AUSTRALIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 362 AUSTRALIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 363 AUSTRALIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 364 AUSTRALIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 365 SOUTH KOREA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 366 SOUTH KOREA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 367 SOUTH KOREA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 368 SOUTH KOREA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 369 SOUTH KOREA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 370 SOUTH KOREA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 371 SOUTH KOREA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 372 SOUTH KOREA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 373 SOUTH KOREA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 374 SOUTH KOREA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 375 SOUTH KOREA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 376 SOUTH KOREA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 377 SOUTH KOREA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 378 SOUTH KOREA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 379 TAIWAN OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 380 TAIWAN PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 381 TAIWAN CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 382 TAIWAN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 383 TAIWAN RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 384 TAIWAN COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 385 TAIWAN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 386 TAIWAN BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 387 TAIWAN NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 388 TAIWAN INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 389 TAIWAN MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 390 TAIWAN OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 391 TAIWAN OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 392 TAIWAN OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 393 SINGAPORE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 394 SINGAPORE PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 395 SINGAPORE CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 396 SINGAPORE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 397 SINGAPORE RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 398 SINGAPORE COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 399 SINGAPORE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 400 SINGAPORE BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 401 SINGAPORE NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 402 SINGAPORE INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 403 SINGAPORE MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 404 SINGAPORE OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 405 SINGAPORE OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 406 SINGAPORE OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 407 MALAYSIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 408 MALAYSIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 409 MALAYSIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 410 MALAYSIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 411 MALAYSIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 412 MALAYSIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 413 MALAYSIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 414 MALAYSIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 415 MALAYSIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 416 MALAYSIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 417 MALAYSIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 418 MALAYSIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 419 MALAYSIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 420 MALAYSIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 421 THAILAND OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 422 THAILAND PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 423 THAILAND CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 424 THAILAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 425 THAILAND RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 426 THAILAND COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 427 THAILAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 428 THAILAND BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 429 THAILAND NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 430 THAILAND INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 431 THAILAND MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 432 THAILAND OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 433 THAILAND OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 434 THAILAND OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 435 INDONESIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 436 INDONESIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 437 INDONESIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 438 INDONESIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 439 INDONESIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 440 INDONESIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 441 INDONESIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 442 INDONESIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 443 INDONESIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 444 INDONESIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 445 INDONESIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 446 INDONESIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 447 INDONESIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 448 INDONESIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 449 PHILIPPINES OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 450 PHILIPPINES PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 451 PHILIPPINES CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 452 PHILIPPINES BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 453 PHILIPPINES RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 454 PHILIPPINES COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 455 PHILIPPINES BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 456 PHILIPPINES BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 457 PHILIPPINES NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 458 PHILIPPINES INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 459 PHILIPPINES MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 460 PHILIPPINES OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 461 PHILIPPINES OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 462 PHILIPPINES OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 463 VIETNAM OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 464 VIETNAM PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 465 VIETNAM CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 466 VIETNAM BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 467 VIETNAM RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 468 VIETNAM COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 469 VIETNAM BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 470 VIETNAM BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 471 VIETNAM NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 472 VIETNAM INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 473 VIETNAM MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 474 VIETNAM OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 475 VIETNAM OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 476 VIETNAM OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 477 REST OF ASIA-PACIFIC OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 478 MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 479 MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 480 MIDDLE EAST AND AFRICA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 481 MIDDLE EAST AND AFRICA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 482 MIDDLE EAST AND AFRICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 483 MIDDLE EAST AND AFRICA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 484 MIDDLE EAST AND AFRICA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 485 MIDDLE EAST AND AFRICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 486 MIDDLE EAST AND AFRICA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 487 MIDDLE EAST AND AFRICA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 488 MIDDLE EAST AND AFRICA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 489 MIDDLE EAST AND AFRICA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 490 MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 491 MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 492 MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 493 SAUDI ARABIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 494 SAUDI ARABIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 495 SAUDI ARABIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 496 SAUDI ARABIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 497 SAUDI ARABIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 498 SAUDI ARABIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 499 SAUDI ARABIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 500 SAUDI ARABIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 501 SAUDI ARABIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 502 SAUDI ARABIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 503 SAUDI ARABIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 504 SAUDI ARABIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 505 SAUDI ARABIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 506 SAUDI ARABIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 507 EGYPT OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 508 EGYPT PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 509 EGYPT CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 510 EGYPT BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 511 EGYPT RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 512 EGYPT COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 513 EGYPT BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 514 EGYPT BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 515 EGYPT NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 516 EGYPT INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 517 EGYPT MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 518 EGYPT OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 519 EGYPT OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 520 EGYPT OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 521 KUWAIT OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 522 KUWAIT PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 523 KUWAIT CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 524 KUWAIT BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 525 KUWAIT RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 526 KUWAIT COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 527 KUWAIT BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 528 KUWAIT BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 529 KUWAIT NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 530 KUWAIT INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 531 KUWAIT MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 532 KUWAIT OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 533 KUWAIT OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 534 KUWAIT OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 535 SOUTH AFRICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 536 SOUTH AFRICA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 537 SOUTH AFRICA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 538 SOUTH AFRICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 539 SOUTH AFRICA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 540 SOUTH AFRICA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 541 SOUTH AFRICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 542 SOUTH AFRICA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 543 SOUTH AFRICA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 544 SOUTH AFRICA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 545 SOUTH AFRICA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 546 SOUTH AFRICA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 547 SOUTH AFRICA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 548 SOUTH AFRICA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 549 UNITED ARAB EMIRATES OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 550 UNITED ARAB EMIRATES PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 551 UNITED ARAB EMIRATES CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 552 UNITED ARAB EMIRATES BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 553 UNITED ARAB EMIRATES RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 554 UNITED ARAB EMIRATES COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 555 UNITED ARAB EMIRATES BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 556 UNITED ARAB EMIRATES BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 557 UNITED ARAB EMIRATES NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 558 UNITED ARAB EMIRATES INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 559 UNITED ARAB EMIRATES MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 560 UNITED ARAB EMIRATES OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 561 UNITED ARAB EMIRATES OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 562 UNITED ARAB EMIRATES OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 563 ISRAEL OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 564 ISRAEL PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 565 ISRAEL CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 566 ISRAEL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 567 ISRAEL RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 568 ISRAEL COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 569 ISRAEL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 570 ISRAEL BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 571 ISRAEL NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 572 ISRAEL INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 573 ISRAEL MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 574 ISRAEL OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 575 ISRAEL OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 576 ISRAEL OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 577 REST OF MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 578 SOUTH AMERICA OBESITY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 579 SOUTH AMERICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 580 SOUTH AMERICA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 581 SOUTH AMERICA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 582 SOUTH AMERICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 583 SOUTH AMERICA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 584 SOUTH AMERICA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 585 SOUTH AMERICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 586 SOUTH AMERICA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 587 SOUTH AMERICA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 588 SOUTH AMERICA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 589 SOUTH AMERICA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 590 SOUTH AMERICA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 591 SOUTH AMERICA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 592 SOUTH AMERICA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 593 BRAZIL OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 594 BRAZIL PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 595 BRAZIL CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 596 BRAZIL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 597 BRAZIL RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 598 BRAZIL COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 599 BRAZIL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 600 BRAZIL BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 601 BRAZIL NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 602 BRAZIL INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 603 BRAZIL MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 604 BRAZIL OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 605 BRAZIL OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 606 BRAZIL OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 607 ARGENTINA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 608 ARGENTINA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 609 ARGENTINA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 610 ARGENTINA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 611 ARGENTINA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 612 ARGENTINA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 613 ARGENTINA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 614 ARGENTINA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 615 ARGENTINA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 616 ARGENTINA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 617 ARGENTINA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 618 ARGENTINA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 619 ARGENTINA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 620 ARGENTINA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 621 CHILE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 622 CHILE PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 623 CHILE CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 624 CHILE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 625 CHILE RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 626 CHILE COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 627 CHILE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 628 CHILE BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 629 CHILE NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 630 CHILE INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 631 CHILE MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 632 CHILE OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 633 CHILE OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 634 CHILE OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 635 PERU OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 636 PERU PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 637 PERU CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 638 PERU BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 639 PERU RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 640 PERU COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)

TABLE 641 PERU BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)

TABLE 642 PERU BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 643 PERU NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 644 PERU INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 645 PERU MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 646 PERU OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)

TABLE 647 PERU OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 648 PERU OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)

TABLE 649 REST OF SOUTH AMERICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)

List of Figure

FIGURE 1 GLOBAL OBESITY TREATMENT MARKET: SEGMENTATION

FIGURE 2 GLOBAL OBESITY TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL OBESITY TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL OBESITY TREATMENT MARKET: REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL OBESITY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL OBESITY TREATMENT MARKET: LIFELINE CURVE

FIGURE 7 GLOBAL OBESITY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 GLOBAL OBESITY TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL OBESITY TREATMENT MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 GLOBAL OBESITY TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 GLOBAL OBESITY TREATMENT MARKET: SEGMENTATION

FIGURE 12 GLOBAL OBESITY TREATMENT MARKET EXECUTIVE SUMMARY

FIGURE 13 STRATEGIC DECISIONS

FIGURE 14 FIVE SEGMENTS COMPRISE THE GLOBAL OBESITY TREATMENT MARKET , BY TREATMENT TYPE

FIGURE 15 RISING PREVALENCE OF OBESITY IS EXPECTED TO DRIVE THE GROWTH OF GLOBAL OBESITY TREATMENT MARKET FROM 2025 TO 2032

FIGURE 16 THE PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL OBESITY TREATMENT MARKET IN 2025 - 2032

FIGURE 17 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL OBESITY TREATMENT MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2025 TO 2032

FIGURE 18 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR GLOBAL OBESITY TREATMENT MARKET IN THE FORECAST PERIOD OF 2025 TO 2032

FIGURE 19 MARKET OVERVIEW

FIGURE 20 PREVALENCE OF OBESITY IN ADULTS AGE 20 AND OLDER, BY SEX AND AGE: UNITED STATES, AUGUST 2021–AUGUST 2023 SOURCE: CENTERS FOR DISEASE CONTROL AND PREVENTION.

FIGURE 21 SHARE OF PRE-OBESE AND OBESE PERSONS AGED 16 YEARS OR OVER, BY SEX, 2022 (%)

FIGURE 22 GLOBAL OBESITY TREATMENT MARKET: BY TREATMENT TYPE, 2024

FIGURE 23 GLOBAL OBESITY TREATMENT MARKET: BY TREATMENT TYPE, 2025-2032 (USD THOUSAND)

FIGURE 24 GLOBAL OBESITY TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2025-2032)

FIGURE 25 GLOBAL OBESITY TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 26 GLOBAL OBESITY TREATMENT MARKET: BY AGE GROUP, 2024

FIGURE 27 GLOBAL OBESITY TREATMENT MARKET: BY AGE GROUP, 2025-2032 (USD THOUSAND)

FIGURE 28 GLOBAL OBESITY TREATMENT MARKET: BY AGE GROUP, CAGR (2025-2032)

FIGURE 29 GLOBAL OBESITY TREATMENT MARKET: BY AGE GROUP, LIFELINE CURVE

FIGURE 30 GLOBAL OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024

FIGURE 31 GLOBAL OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)

FIGURE 32 GLOBAL OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)

FIGURE 33 GLOBAL OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 34 GLOBAL OBESITY TREATMENT MARKET: BY PATIENT TYPE, 2024

FIGURE 35 GLOBAL OBESITY TREATMENT MARKET: BY PATIENT TYPE, 2025-2032 (USD THOUSAND)

FIGURE 36 GLOBAL OBESITY TREATMENT MARKET: BY PATIENT TYPE, CAGR (2025-2032)

FIGURE 37 GLOBAL OBESITY TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 38 GLOBAL OBESITY TREATMENT MARKET: SNAPSHOT (2024)

FIGURE 39 GLOBAL OBESITY TREATMENT MARKET: COMPANY SHARE 2024 (%)

FIGURE 40 NORTH AMERICA OBESITY TREATMENT MARKET: COMPANY SHARE 2024 (%)

FIGURE 41 EUROPE OBESITY TREATMENT MARKET: COMPANY SHARE 2024 (%)

FIGURE 42 ASIA-PACIFIC OBESITY TREATMENT MARKET: COMPANY SHARE 2024 (%)

View Detailed Information

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

What is the current market size of the global obesity treatment market?

The global obesity treatment market size was valued at USD 38.46 million in 2024.

What is the expected growth rate of global obesity treatment market?

The global obesity treatment market is to grow at a CAGR of 14.7% during the forecast period of 2025 to 2032.

What are the primary segments covered in the global obesity treatment market report?

The global obesity treatment market is segmented into four notable segments based on treatment type, age group, distribution channel and patient type. On the basis of treatment type, the market is segmented into pharmacological treatments (anti-obesity drugs), bariatric surgery, behavioral & lifestyle therapy, non-invasive/ endoscopic procedures, and medical devices & technologies. On the basis of age group, the market is segmented into adult obesity treatment, geriatric obesity treatment, and pediatric obesity treatment. On the basis of distribution channel, the market is segmented into online pharmacies, retail pharmacies, weight management clinics, hospital pharmacies, and wellness & fitness centers. On the basis of patient type, the market is segmented into class III, class II, and class I.

Who are major players in global obesity treatment market?

Companies such as Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Medtronic (U.S.), Boston Scientific Corporation (U.S.), Johnson & Johnson Services, Inc. (U.S.) are the major companies in the global obesity treatment market.

Global Obesity Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Obesity Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Circumvent the Tariff challenges with an agile supply chain Consulting

Global Obesity Treatment Market

CAGR : 14.70 %

Global Obesity Treatment Market Size

Global Obesity Treatment Market Analysis

Global Obesity Treatment Market Scope

Global Obesity Treatment Market Share

Latest Developments in Global Obesity Treatment Market

Get online access to the report on the World's First Market Intelligence Cloud

Table of Content

List of Table

List of Figure

Research Methodology

Customization Available

Frequently Asked Questions

Claudio Rondena Group Business Development & Strategic Marketing Director,
C.O.C Farmaceutici SRL

David Manning - Thermo Fisher Scientific Director, Global Strategic Accounts,

Manager - Market Analytics, Uriah D. Avila - Zeus Polymer Solutions

Business Development Manager, (Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC

Business Intelligence and Analytics, Ipsen Biopharm Limited

Competition Analyst, Basler Web

Marketing Director, Buhler Group

COO, A global leader providing Drug Delivery Services

Marketing Director, Philips Healthcare

Product manager, Fujifilms

Investor relations, GE Healthcare

Market Analyst, Medincell

Andrew - Senior Global Marketing Manager, Medtronic (US)

Amarildo - Manager, Global Strategic Alignment MasterCard

Tor Hammer Green Nexus LLc

Tommaso Finocchiaro Market Intelligence Specialist Nippon Gasses

Yuki Kopyl (Asian Business Development Department) UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Reports

Market Insights

Support

Solutions

Global Obesity Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Obesity Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Circumvent the Tariff challenges with an agile supply chain Consulting

Global Obesity Treatment Market

CAGR : 14.70 %

Global Obesity Treatment Market Size

Global Obesity Treatment Market Analysis

Global Obesity Treatment Market Scope

Global Obesity Treatment Market Share

Latest Developments in Global Obesity Treatment Market

Get online access to the report on the World's First Market Intelligence Cloud

Table of Content

List of Table

List of Figure

Research Methodology

Customization Available

Frequently Asked Questions

Browse Related Pages

Claudio Rondena Group Business Development & Strategic Marketing Director,C.O.C Farmaceutici SRL

David Manning - Thermo Fisher Scientific Director, Global Strategic Accounts,

Manager - Market Analytics, Uriah D. Avila - Zeus Polymer Solutions

Business Development Manager, (Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC

Business Intelligence and Analytics, Ipsen Biopharm Limited

Competition Analyst, Basler Web

Marketing Director, Buhler Group

COO, A global leader providing Drug Delivery Services

Marketing Director, Philips Healthcare

Product manager, Fujifilms

Investor relations, GE Healthcare

Market Analyst, Medincell

Andrew - Senior Global Marketing Manager, Medtronic (US)

Amarildo - Manager, Global Strategic Alignment MasterCard

Tor Hammer Green Nexus LLc

Tommaso Finocchiaro Market Intelligence Specialist Nippon Gasses

Yuki Kopyl (Asian Business Development Department) UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Claudio Rondena Group Business Development & Strategic Marketing Director,
C.O.C Farmaceutici SRL